Head to Head Analysis: BR Biopharma (NASDAQ:BRBI) versus PennantPark Investment (NASDAQ:PNNT)

PennantPark Investment (NASDAQ:PNNT) and BR Biopharma (NASDAQ:BRBI) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares PennantPark Investment and BR Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PennantPark Investment	$21.50 million	11.22	$48.85 million	$0.16	23.09
BR Biopharma	$2.23 billion	0.06	$31.36 million	$0.08	140.81

PennantPark Investment has higher earnings, but lower revenue than BR Biopharma. PennantPark Investment is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PennantPark Investment and BR Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PennantPark Investment	11.33%	11.59%	4.23%
BR Biopharma	N/A	N/A	N/A

Insider & Institutional Ownership

26.6% of PennantPark Investment shares are owned by institutional investors. 3.0% of PennantPark Investment shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

PennantPark Investment pays an annual dividend of $0.48 per share and has a dividend yield of 13.0%. BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.7%. PennantPark Investment pays out 300.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. PennantPark Investment has raised its dividend for 1 consecutive years. PennantPark Investment is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for PennantPark Investment and BR Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PennantPark Investment	1	3	1	0	2.00
BR Biopharma	1	0	0	0	1.00

PennantPark Investment currently has a consensus price target of $5.10, suggesting a potential upside of 38.02%. Given PennantPark Investment’s stronger consensus rating and higher possible upside, equities analysts plainly believe PennantPark Investment is more favorable than BR Biopharma.

Summary

PennantPark Investment beats BR Biopharma on 14 of the 16 factors compared between the two stocks.

About PennantPark Investment

PennantPark Investment Corporation, a business development company is a private equity fund specializes in direct and mezzanine investments in middle market companies. It invests in the form of mezzanine debt, senior secured loans, and equity investments. The fund typically invests in buildings and real estate, hotels, gaming and leisure, technology, telecommunications, transportation, information technology services, electronics, healthcare & pharmaceuticals, education and childcare, financial services, printing and publishing, consumer products, business services, energy & Related Services and utilities, distribution, oil and gas, media, environmental services, aerospace and defense, building materials, capital equipment, chemicals, plastics, & rubber, food & beverage, wholesale, manufacturing and basic industries and retail. It invests in equity securities and debt transactions through preferred stock, common stock, warrants, options, senior secured debt, subordinated debt, subordinated loans, first lien debt, mezzanine loans, and distressed debt securities and private equity co-investments. It seeks to invest in companies based in the United States. The fund seeks to invest between $10 million and $100 million cross the capital structure (senior secured loans, subordinated debt, and other investments) in its portfolio companies with EBITDA between $10 to $50 million. Its mezzanine loans, senior secured loans, and other investments in its portfolio companies are between $15 million and $50 million. The fund may also make non-control equity and debt investments.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.